Loading
A phase 2 trial of iparomlimab and tuvonralimab, cisplatin and carboplatin in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) is a phase 2, randomised interventional study registered as NCT07413601 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 78 participants, started 2026-02-10 and due to reach its primary completion in 2029-02-10. Interventions recorded: QL1706; Cisplatin/ Carboplatin. Conditions listed: Triple Negative Breast Cancer Metastatic. Triple-negative eligibility wording from the registry: "* Locally advanced or metastatic triple negative breast cancer confirmed by histopathology that is not suitable for curative treatment and cannot be treated surgically (Defined as negative for HER2, ER and PR expression according to the latest ASCO/CAP guidelines);". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Cisplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Iparomlimab and tuvonralimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Cisplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/